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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.10.027Background: Percutaneous pulmonary valve replacement has recently been intro-
duced and is under investigation in humans. This technique is, however, limited to
patients with a right ventricular outflow tract that does not exceed 22 mm in
diameter. We report our experience of off-pump pulmonary valve replacement using
a hybrid approach in animals with large right ventricular outflow tracts.
Methods: Eight ewes were included in the protocol and were equally divided into 2
groups. A left thoracotomy was first performed, and the main pulmonary artery was
banded by using 2 radiopaque rings with a diameter of 18 mm that allowed for
further pulmonary valve replacement. We then intended to implant a valved stent
either percutaneously (group 1) or through a transventricular approach (group 2). All
animals were killed after valve implantation. The operation allowed the pulmonary
diameter to be reduced from 30 to 17.6 mm.
Results: The right ventricular pressure did not significantly increase after reduction
of the pulmonary artery diameter (25 vs 36 mm Hg). Subsequent pulmonary valve
replacement through a percutaneous or a transventricular approach was always
possible without any requirement for extracorporeal circulation. All devices were
successfully delivered inside the pulmonary artery banding and were functioning
perfectly at early evaluation.
Conclusions: Implantation of a pulmonary valve is possible in ewes through a hybrid
approach when the right ventricular outflow tract exceeds 22 mm in diameter. This
involves both surgeons and interventionists and allows for a staged procedure in which
the valvulation is performed percutaneously or, for a combined hybrid approach, in
which the valve is implanted off pump transventricularly during the same operation.
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ETPercutaneous pulmonary valve replacement hasrecently been introduced, and early clinicalhuman experience has been reported.1-6 Thedevice we developed is a biological valveharvested from the bovine jugular vein andmounted in a balloon-expandable stent. Be-
cause of valve availability, indications in humans are pres-
ently limited to patients who have a right ventricular out-
flow tract (RVOT) that does not exceed 22 mm in diameter.
Unfortunately, patients who underwent transannular patch
repair of tetralogy of Fallot during infancy can have pul-
monary trunks that often exceed 30 mm in diameter, and
this makes percutaneous implantation technically impossi-
ble with the current approach.1-3,7-9 These patients are the
most common group of patients who require pulmonary
valve replacement. To broaden the indications of percuta-
neous replacement of the pulmonary valve to the entire
anatomic spectrum of pulmonary regurgitation, we recently
reported the use of a self-expandable stent that allows
downsizing the diameter of the vessel to the available valve
diameter.10 In tortuous pulmonary anatomy, as frequently
seen after surgery in patients with a tetralogy of Fallot, the
deployment of such a stent could be hampered. To encom-
pass this problem, we imagined a hybrid approach that
involved both surgeons and cardiac interventionists in
which the first step would be to surgically perform a pul-
monary artery (PA) banding to a diameter that allows for a
further pulmonary valve replacement (PVR). We therefore
designed an experimental study to evaluate this alternative
strategy aiming at the off-bypass implantation of a valved
stent in pulmonary position in large RVOTs.
Methods
Device Preparation for Downsizing the Diameter of
the Pulmonary Trunk
Two rings made of a 0.27-mm self-expandable alloy wire encap-
sulated in a plastic tube were prepared (AMF, Reuilly, France;
Figure 1). The rings had a spontaneous diameter of 18 mm and
were “opened.” This allowed for the structure to be straightened
and placed around the PA. These radiopaque rings were designed
to support the valved stent and to help its precise placement under
fluoroscopic guidance.
Preparation of the Valved Stent for PVR
The valved stent was prepared as previously reported with the use
of an 18-mm bovine jugular venous valve mounted in a balloon-
expandable CP stent (NuMED Inc, Hopkinton, NY).1
The Delivery System
The delivery system consisted of a front-loading long sheath
premounted with a 22-mm balloon-in-balloon catheter inside
(NuMED). The distal part of the sheath was larger than the
proximal part, thus liberating extra space for valved stent place-
ment. The outer size of the delivery system was 18F distally and
14F proximally. The length of the distal part was 5 cm. The sheath
832 The Journal of Thoracic and Cardiovascular Surgery ● Aprifreely slid over the device. At the tip of the catheter, a 1-cm-long
dilator was glued to allow a smooth transition between the tip and
the sheath, thus limiting the risk of traumatizing the vessel or
ventricle at the time of insertion.
Repartition of the Animals and Grouping
Eight ewes weighing 60 to 70 kg were included. Animals were
equally divided into 2 groups regarding the type of hybrid ap-
proach. All animals had a surgical reduction of the PA diameter
through a thoracotomy by using the device described previously
without cardiopulmonary bypass. In the first group (4 animals), we
then intended to implant an 18-mm valved stent percutaneously
through the left jugular vein. In the second group (4 animals), we
expected to implant a valve through a small right ventriculotomy
into the previously placed PA banding by using the same thora-
cotomy. This study was approved by the ethical committee of our
institution, and animals received care in accordance with the
“Principles of Laboratory Animal Care” and the “Guide for the
Care and Use of Laboratory Animals.”
PA Banding
Ewes were sedated with intravenous injection of thiopental sodium
(Pentothal; 10 mg/kg body weight), placed in the lateral position,
intubated, and ventilated with 100% oxygen and 1% halothane.
Anesthesia was maintained with halothane (0.5%-3%). Cardiac
and respiratory functions were monitored throughout the proce-
dure. A left thoracotomy was performed in the fourth intercostal
space. After the thoracotomy was completed, all ewes underwent
catheterization for anatomic and hemodynamic evaluations before
PA banding. For that purpose, the left jugular vein was prepared
for catheterization, and a 7F sheath was introduced. Heparin (100
Figure 1. In vitro views of the various phases of the procedure. A,
The ring used for the pulmonary artery banding is made of nitinol
and has a spontaneous diameter of 18 mm. B, The ring is opened
and straightened before its passage around the main pulmonary
artery, represented by the glass tube. C, View showing the aspect
of the ring around a glass tube. D, View showing the aspect of a
stent placed inside the glass tube after placement of 2 rings.UI/kg) was administered once after thoracotomy and vascular
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ETaccess were obtained. A ring was straightened and inserted prox-
imally around the main PA. A second ring was then placed 2 cm
more distally than the first one. Particular attention was taken not
to traumatize the vessel and the surrounding structures when
passing the rings around the main PA. The rings were then sutured
with a discontinuous suture by using a 4-0 propylene thread
anteriorly to disable their displacement during stent implantation.
These sutures did not, however, impinge the possibility for the ring
to open when dilated with a balloon of a larger diameter. Because
of the intrinsic properties of the material used to manufacture the
bandings, each ring tends to recover its spontaneous diameter, thus
adding some dynamic support for the valve to be implanted.
Pulmonary Valve Insertion
In both groups, the valved stent was loaded into the previously
described 18F delivery system (NuMED). In group 1, the
loaded delivery system was inserted through the jugular vein
over a previously positioned 0.035-inch extrastiff guidewire
(Amplatzer; AGA Medical Corporation, Golden Valley, Minn).
The stent was advanced, uncovered, and deployed in the pul-
monary trunk between the 2 markers of the PA banding by
subsequently inflating the inner and the outer balloon catheters.
After valve insertion, the balloons were finally deflated and
retrieved with the delivery system. The valved stent was left in
the deployed position. In animals from group 2, a 10-mm large
purse-string suture was performed with 4-0 polypropylene ap-
proximately 3 cm below the native pulmonary valve. The right
ventricle was punctured in the middle of that purse in the
direction of the PAs, and a wire was inserted in the lumen of the
needle, advanced in the right PA, and exchanged for a right
coronary catheter (Cordis, Montargis, France). Under fluoro-
scopic guidance, a 0.035-inch extrastiff guidewire (Amplatzer)
was positioned in the distal right PA. The valved stent was
finally inserted as previously described for animals from group
1. Bleeding was controlled by tightening of the purse string.
After the procedure, the ventriculotomy was closed with the
TABLE 1. Hemodynamic data before pulmonary artery ban
Animal no.
Diameter of the main
pulmonary artery (mm) RV
1 30
2 32
3 31
4 28
5 30
6 29
7 32
8 28
Mean 30 2
SD 1.6
RVP, Right ventricular pressure; PAP, pulmonary artery pressure; PAo, ao
*Data are systolic/diastolic/end-diastolic.
†Data are systolic/diastolic/mean.suture of the purse.
The Journal of ThoraciCardiac Catheterization and Testing of the Implanted
Device
Right ventricular and pulmonary pressures were measured before
and after PA banding and after the implantation of the valved stent
to determine the gradient across the banding and the stent. Angio-
graphic evaluation consisted of pulmonary injection and right
ventriculography. Angiograms were performed (1) before the pro-
cedure, to define the anatomy of the pulmonary root and to
measure the size of the pulmonary trunk; (2) after PA banding; and
(3) before the animals were killed, to confirm the appropriate
position of the valved stent and its sealing and to verify the
function of the implanted valve.
Graft Retrieval
All animals were killed 1 hour after the valve implantation. Before
harvesting, heparin (300 UI/kg) was given intravenously. The
heart and the lungs were retrieved together in 1 block. The pul-
monary vascular tree was examined to determine the position of
the implanted device in relation to the PA banding. The device and
the band were then harvested with a section of the PA and rinsed
to remove excess intraluminal blood. All grafts were inspected,
and the competence of the valve was grossly tested by passing
fluid in the graft.
Results
The mean size of the pulmonary trunk was 30  1.6 mm
(range, 28-32 mm; Table 1). PA banding was possible in all
8 ewes without any macroscopic damage to the main PA or
the surrounding structures. After the left thoracotomy was
performed, the PA banding was achieved in less than 30
minutes in all animals (Figure 2). The mean diameter of the
main PA decreased significantly to 17.6  0.5 mm (P 
.00001). The right ventricular systolic pressure increased
from 25  3 mm Hg to 36  6 mm Hg (P  .003; Table
2). The PA pressures decreased slightly from 24/11/15 mm
Hg to 22/10/14 mm Hg (systolic/diastolic/mean) after cre-
Hg)* PAP (mm Hg)† PAo (mm Hg)†
/6 19/9/12 103/62/75
/8 22/13/16 95/56/69
/4 28/11/17 110/65/80
/5 27/11/16 94/58/70
/5 24/12/16 115/65/82
/7 25/10/15 114/68/83
/6 23/8/13 89/54/66
/4 24/14/17 108/57/74
/5.9 24/11/15.3 103.5/60.6/74.9
/1.5 2.8/2/1.8 9.8/5.1/6.3
ressure.ding
P (mm
20/0
22/0
28/0
30/0
25/0
28/0
25/0
24/0
5.3/0
3.3/0
rtic pation of the band (P  .27, .39, and .22, respectively).
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ET All 8 devices were successfully implanted by using a
22-mm balloon catheter. After vascular access was granted,
mean procedural times in animals from groups 1 and 2 were
10 minutes (range, 8-15 minutes) and 6 minutes (range, 4-7
minutes), respectively. The mean diameter of the main PA
increased significantly after PVR to 21.1  0.8 mm as
compared with postbanding (P  .00001) and prebanding
(P  .00001) procedures. The mean systolic transprosthetic
gradient was 14  9.7 mm Hg (range, 0-26 mm Hg; Table
1). This gradient decreased when comparing postbanding
and post-PVR evaluations (6.4  2.1 mm Hg vs 14  9.7
mm Hg) but remained significantly higher than basal data
(6.4  2.1 mm Hg vs 1.25  1.3 mm Hg; Tables 3 and 4).
The mean ratio between the right ventricular and aortic
pressures was less than 35% (27.8%  3.6%) in all animals
(range, 24%-34.7%; Table 3). There was no early migration
of any valved stents.
Angiographic evaluation revealed that the implants were
in the desired position (Figure 3) between the 2 radiopaque
markers and confirmed the sealing of the device, showing
no leak between the valved stent and the banded pulmonary
wall. Valves were competent angiographically and hemo-
Figure 2. Angiograms before (A) and after (B) the pulmo
and the radiopaque marker of the rings.
TABLE 2. Hemodynamic data after pulmonary artery bandi
Animal no.
Diameter of the main
pulmonary artery (mm) RVP (mm Hg)*
1 18 38/0/5
2 17 44/0/8
3 18 36/0/6
4 17 34/0/5
5 17 38/0/4
6 18 30/0/8
7 18 42/0/6
8 18 26/0/5
Mean 17.6 36/0/5.9
SD 0.5 6/0/1.5
RVP, Right ventricular pressure; PAP, pulmonary artery pressure; PAo, ao
*Data are systolic/diastolic/end-diastolic.
†Data are systolic/diastolic/mean.dynamically (Figure 3). As expected, at autopsy, a small
834 The Journal of Thoracic and Cardiovascular Surgery ● Aprihematoma of the pulmonary wall was found underneath the
rings in all animals (Figure 4). No extravasation of blood
was found. Inspection of implanted valves showed thin and
mobile leaflets.
Discussion
Patients who have undergone transannular patch repair of
tetralogy of Fallot during infancy have pulmonary trunks
that often exceed 22 mm in diameter, and this makes per-
cutaneous implantation technically impossible with the cur-
rent approach.1-3,7-9 To encompass this difficulty and to
broaden the indications of percutaneous pulmonary valve
implantation to the entire spectrum of patients, we designed
and recently reported the use of a preshaped self-expandable
stent that has 2 different diameters. This stent was con-
structed from a nitinol wire in the shape of a conduit with a
central restriction of its diameter (AMF). The extremities
had a spontaneous diameter of 30 mm, and the central
restricted part was calibrated to shelter an 18-mm valve. The
overall length of the deployed device was 5.5 cm, and the
restricted part measured 15 mm. A polytetrafluoroethylene
membrane was sutured on the device to ensure the sealing
artery banding, showing the reduction of the diameter
PAP (mm Hg)† PAo (mm Hg)†
RV to PA systolic
gradient (mm Hg)
18/10/13 96/49/65 20
18/12/14 110/55/73 26
22/10/14 107/58/74 14
27/12/17 88/55/66 7
20/8/12 124/63/83 18
27/11/16 92/49/63 3
18/9/12 113/62/79 24
26/10/15 98/54/67 0
22/10.2/14.1 103.5/55.6/71.3 14
4.1/1.4/1.8 12.1/5.2/7.2 9.7
ressure; RV, right ventricle; PA, pulmonary artery.naryng
rtic pof the device. In reported experiments, implantation of these
l 2005
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ETstents was feasible in nearly all included ewes, thus permit-
ting the reduction of the pulmonary trunk to the desired
diameter with only a slight increase of right ventricular
pressure.10 Despite excellent preliminary results, several
limitations to the study urged us to develop alternative
approaches. The anatomy of the RVOT varies greatly be-
tween patients, and tortuous pulmonary anatomy is not
infrequently seen in patients who undergo operation in
infancy for tetralogy of Fallot after long-standing pulmo-
nary regurgitation. During the last year, we have been
imaging many of these patients and have tried to virtually
implant this device (data not shown). In approximately 50%
of patients, the device as initially designed was considered
implantable.
Elsewhere, its deployment was unsatisfactory because of
tortuous anatomy with a great change in diameter through-
out the length of the main pulmonary artery, shortness of the
main pulmonary artery, or both. These drawbacks led to
partial deployment, lengthening, overall diameter reduction,
and inappropriate sealing of the device with periprosthetic
leakage. During use of a valved device, the restriction of the
TABLE 3. Hemodynamic data after pulmonary valve insert
Animal
no.
Diameter of the main
pulmonary artery (mm) RVP (mm Hg)* PAP (
1 20 25/0/7 16/1
2 21 26/0/7 19/1
3 20 28/0/5 20/1
4 21 29/0/6 25/1
5 22 28/0/5 22/1
6 22 30/0/7 24/1
7 21 27/0/5 24/1
8 22 33/0/6 25/1
Mean 21.1 28.3/0/6 21.9/1
SD 0.8 2.5/0/0.9 3.3/1
RVP, Right ventricular pressure; PAP, pulmonary artery pressure; PAo, a
pulmonary artery.
*Data are systolic/diastolic/end-diastolic.
†Data are systolic/diastolic/mean.
TABLE 4. Comparison among hemodynamic data obtained
valve insertion
Variable Base
Diameter of the MPA (mm) 30 1.6
RVP systolic (mm Hg) 25.3 3.3
RV to PA systolic gradient (mm Hg) 1.25 1.3
PAP diastolic (mm Hg) N/A
Data are mean  SD. All data from Tables 1 to 3 were compared 2 by 2 (b
Only statistically significant data are shown in this table. MPA, Main pulmo
artery pressure; RV, right ventricle; PA, pulmonary artery.
*Significant for all 3 comparisons.central part could additionally interfere with valve geometry
The Journal of Thoraciand function. We therefore investigated alternative ap-
proaches and hypothesized that a hybrid approach with
cooperation between surgeons and cardiac interventionists
would permit a stepwise implantation without necessitating
extracorporeal circulation. Through a left thoracotomy, the
PA was banded by using 2 radiopaque rings; this allowed
for subsequent off-pump implantation of a pulmonary
valve. We then investigated the possibility of inserting the
valve during the thoracotomy through a right ventriculot-
omy or after the thoracotomy through a percutaneous ap-
proach. We succeeded in inserting a pulmonary valve by
using both approaches with only a slight increase of the
right ventricular pressure: all right ventricular pressure was
less than 33 mm Hg. That kind of increase should have
limited repercussions even in patients with a failing right
ventricle. In patients with preexisting increased right ven-
tricular pressure, any additional obstruction could be dele-
terious. This should be avoided by aggressively treating
significant PA stenosis before PVR.
In humans, both approaches could be similarly used.
Each procedure has specific drawbacks and advantages. We,
g)† PAo (mm Hg)†
RV to PA systolic
gradient (mm Hg)
Type of
implantation
104/62/76 9 P
98/52/67 7 TV
100/60/73 8 P
94/58/70 4 TV
108/62/77 6 P
104/60/75 6 TV
110/60/77 3 P
95/50/65 8 TV
5.3 101.6/58/72.5 6.4
5.8/4.5/4.7 2.1
pressure; P, percutaneous; TV, transventricular; RV, right ventricle; PA,
re the procedure, after PA banding, and after pulmonary
ter PA banding After valve insertion P value
17.6 0.5 21.1 0.8 .00001*
36 6 N/A .0003
N/A 6.4 2.1 .0001
10.2 1.4 11.9 1.2 .024
 PA banding, base  valve insertion, and PA banding  valve insertion).
rtery; RVP, right ventricular pressure; N/A, not applicable; PAP, pulmonaryion
mm H
1/13
3/15
2/15
1/16
0/14
2/16
4/17
2/16
1.9/1
.2/1.3
orticbefo
Af
ase 
nary ahowever, favor the transventricular approach because (1)
c and Cardiovascular Surgery ● Volume 129, Number 4 835
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ETbanding and valvulation are performed during the same
procedure; (2) rescue extracorporeal circulation can be per-
formed faster; and (3) the stent can be secured by stitches,
thus limiting the risk of secondary stent migration. Scarring
on the right ventricle does not seem to be a problem because
the right ventriculotomy can be performed on the site of the
previous ventriculotomy. In patients with no history of
surgery, a percutaneous approach during the operation or
after recovery should be preferred to the transventricular
approach to avoid the risk of late arrhythmia and sudden
death, which might result from a right ventriculotomy.
This study had several limitations. First, only animals
with normal RVOTs were evaluated. Because the aneurys-
mal dilatation of the RVOT as seen in Fallot patients ap-
pears late after surgical repair, a similar setting was impos-
sible to achieve in animals. Similarly, Fallot patients are
often operated on several times, and this makes the chest
opening and dissection more difficult each time. The cre-
ation of the banding could, in theory, be difficult in such
situation because of the size discrepancy between the native
RVOT and the banding to be created and because of the
previous interventions. This needs to be addressed before
human application. Second, the investigated approaches do
not retrieve the aneurysmal and akinetic RVOT. This could
limit the improvement of the right ventricular function of
the patients and would favor on-pump surgical procedures
with resection of the aneurysmal part. This should, however,
be balanced by the repercussions of cardiopulmonary by-
Figure 3. Angiograms showing the implantation of the
The valved stent has been advanced from the jugular ve
to expand the stent. C, Proximal angiogram showing th
the competence of the implanted valve.pass on ventricular function. Moreover, the superiority of
836 The Journal of Thoracic and Cardiovascular Surgery ● ApriPVR with resection of the aneurysmal RVOT over PVR
without remodeling of the RVOT has not been clearly
established.11 Randomized controlled studies will be neces-
sary to address this question in which various techniques,
including the off-pump hybrid approach and on-pump PVR
with and without remodeling of the RVOT, should be com-
pared prospectively. Third, because no chronic data are
available, the long-term performance of this approach re-
mains unknown and requires more experimental studies
before human application. In particular, the risks of second-
ary erosion and migration of the rings and valved stents
should be assessed more accurately. However, both theo-
retical risks of migration can be reduced or canceled. For
insertion of each ring around the PA, limiting the dissection
of the PA posteriorly to 2 small spaces rather than 1 large
space is a way to limit the tendency of the bands to migrate.
Additionally, suturing the rings to the anterior wall of the
PA, as we did, might also reduce the risk of band migration.
Similarly, to avoid stent migration, it can be secured by
stitches at the level of the rings at the time of the implan-
tation. Flaring the end part of the stent by using a larger
balloon might additionally help to reduce this risk.
In conclusion, here we report new insights into PVR
through a hybrid approach. We resolved the present limita-
tion of percutaneous implantation in the large RVOT by first
reducing the diameter of the RVOT. This approach does not
require cardiopulmonary bypass and allows for further pul-
monary valve insertion, either percutaneously or through a
d stent through a percutaneous approach (group 1). A,
the main pulmonary artery. B, The balloons are inflated
ling of the device. D, Distal angiogram demonstratingvalve
in in
e seasmall ventriculotomy. This study provides technical infor-
l 2005
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ETmation regarding the method of RVOT modification and
valve implantation, but long-term performance was not
evaluated and will require further long-term studies before
clinical application. If applicable in humans, this approach
will lead to the extension of the present indications to
off-pump replacement of the pulmonary valve by using the
available device, regardless of the size and anatomy of the
PA.
We thank the veterinary surgeons of the animal laboratory and
NuMED Inc for its technical support.
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